Epidermal homeostasis: The role of the growth hormone and insulin-like growth factor systems

被引:151
|
作者
Edmondson, SR [1 ]
Thumiger, SP [1 ]
Werther, GA [1 ]
Wraight, CJ [1 ]
机构
[1] Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Ctr Hormone Res, Parkville, Vic 3052, Australia
关键词
FACTOR-BINDING PROTEIN-3; FACTOR-I RECEPTOR; MESSENGER-RIBONUCLEIC-ACID; GENETICALLY-MODIFIED KERATINOCYTES; CULTURED HUMAN KERATINOCYTES; SENESCENT HUMAN FIBROBLASTS; COLLAGEN GENE-EXPRESSION; HUMAN SKIN KERATINOCYTES; NORMAL HUMAN MELANOCYTES; BREAST-CANCER CELLS;
D O I
10.1210/er.2002-0021
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
GH and IGF-I and -II were first identified by their endocrine activity. Specifically, IGF-I was found to mediate the linear growth-promoting actions of GH. It is now evident that these two growth factor systems also exert widespread activity throughout the body and that their actions are not always interconnected. The literature highlights the importance of the GH and IGF systems in normal skin homeostasis, including dermal/epidermal cross-talk. GH activity, sometimes mediated via IGF-I, is primarily evident in the dermis, particularly affecting collagen synthesis. In contrast, IGF action is an important feature of the dermal and epidermal compartments, predominantly enhancing cell proliferation, survival, and migration. The locally expressed IGF binding proteins play significant and complex roles, primarily via modulation of IGF actions. Disturbances in GH and IGF signaling pathways are implicated in the pathophysiology of several skin perturbations, particularly those exhibiting epidermal hyperplasia (e.g., psoriasis, carcinomas). Additionally, many studies emphasize the potential use of both growth factors in the treatment of skin wounds; for example, burn patients. This overview concerns the role and mechanisms of action of the GH and IGF systems in skin and maintenance of epidermal integrity in both health and disease.
引用
收藏
页码:737 / 764
页数:28
相关论文
共 50 条
  • [1] Growth hormone, the insulin-like growth factor axis, insulin and cancer risk
    Clayton, Peter E.
    Banerjee, Indraneel
    Murray, Philip G.
    Renehan, Andrew G.
    NATURE REVIEWS ENDOCRINOLOGY, 2011, 7 (01) : 11 - 24
  • [2] Both epidermal growth factor and insulin-like growth factor receptors are dispensable for structural intestinal adaptation
    Sun, Raphael C.
    Diaz-Miron, Jose L.
    Choi, Pamela M.
    Sommovilla, Joshua
    Guo, Jun
    Erwin, Christopher R.
    Warner, Brad W.
    JOURNAL OF PEDIATRIC SURGERY, 2015, 50 (06) : 943 - 947
  • [3] Downstream Insulin-Like Growth Factor
    Pfaeffle, Roland
    Kiess, Wieland
    Klammt, Juergen
    DEVELOPMENTAL BIOLOGY OF GH SECRETION, GROWTH AND TREATMENT, 2012, 23 : 42 - 51
  • [4] Insulin-Like Growth Factor Pathway
    Haluska, Paul
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S478 - S479
  • [5] Insulin-Like Growth Factor and Epidermal Growth Factor Signaling in Breast Cancer Cell Growth: Focus on Endocrine Resistant Disease
    Voudouri, Kallirroi
    Berdiaki, Aikaterini
    Tzardi, Maria
    Tzanakakis, George N.
    Nikitovic, Dragana
    ANALYTICAL CELLULAR PATHOLOGY, 2015, 2015
  • [6] Response to Growth Hormone Treatment in a Patient with Insulin-Like Growth Factor 1 Receptor Deletion
    Mahmoud, Ranim
    Naidu, Ajanta
    Risheg, Hiba
    Kimonis, Virginia
    JOURNAL OF CLINICAL RESEARCH IN PEDIATRIC ENDOCRINOLOGY, 2017, 9 (04) : 380 - 386
  • [7] Growth Hormone, Insulin-Like Growth Factor-1, and the Kidney: Pathophysiological and Clinical Implications
    Kamenicky, Peter
    Mazziotti, Gherardo
    Lombes, Marc
    Giustina, Andrea
    Chanson, Philippe
    ENDOCRINE REVIEWS, 2014, 35 (02) : 234 - 281
  • [8] The insulin-like growth factor system and sarcomas
    Rikhof, Bart
    de Jong, Steven
    Suurmeijer, Albert J. H.
    Meijer, Coby
    van der Graaf, Winette T. A.
    JOURNAL OF PATHOLOGY, 2009, 217 (04) : 469 - 482
  • [9] Insulin-Like Growth Factor Pathway and the Thyroid
    Smith, Terry J.
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12